RGCs represent one key target cell population for optogenetics (Farrar et al., 2014; Gaub et al., 2014), and hence the Nefh promoter characterized in the current study, in principle, may also be of value in the design of future optogenetic-based gene therapies for IRDs. The gene discussed is NEFH; the disease is respiratory distress syndrome in premature infants.